Clinical trial
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
NCT01077297 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 31, 2010
- Completion date
- September 30, 2011
- Enrollment
- 3 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.